Regenerative Medicine
to reverse bone-loss
Bone targeting platform to treat rare bone-diseases. Stepping Stones to The Future of Bone Regeneration.
SEM osteoblasts, magnification 400X
Mesentech developed a novel that can deliver medicines selectively to the bone. Our first drug candidate, C3, reverses bone loss.
Mesentech's bone anabolic drug conjugates will be incrementally developed as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. A topical formulation is being developed as a bone graft material to speed osseointegration in orthopedic and oral-maxillofacial indications while avoiding the cost and morbidity associated with harvesting self-donor material for autografts.
Executive Team
Robert Young
Founder & President
• 30+ years leading discovery at Merck resulting in $80B+ in revenue from development of Singulair®. Vioxx®, Arcoxia®, Previcox®, Tredaptive® and odanacatib • Recipient of Heros of Chemistry award and the Order of Canada award • Two time recipient of Prix Galien (UK and Canada)
Jon Polak
CEO
• Head of Business Development at Novateur Ventures • Founder and former CEO of Datapoint Diagnostics • Co-founder of C7bio • Deep international experience in clinical development, financing, regulatory strategy, pharmaceutical partnerships, recruiting angel investors, asset sale and patenting • Speaks 5 languages having lived and worked in China, Israel, Brazil, US & Canada.
Michael Underhill
Co-founder & Chief Science Officer
• Leading foundational research on mechanisms underlying bone formation • Co-founder of Corigen and Nexigen • Professor of Microbiology & Immunology at UBC
Peter Savas
Executive Chairman
• Serial CEO with 8 positive exists for shareholders • Current CEO of Likeminds • Formerly CEO of Alseres Pharma • Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® trans-dermal patch marketed worldwide to treat Parkinson’s disease • Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials • leadership positions with Bristol Meyers, Waters, Millipore, Genex and Zymark.
Learn more about our
If you are interested in partnering, we’d love to hear from you
Regenerative Medicine
to reverse bone-loss
Bone targeting platform to treat rare bone-diseases. Stepping Stones to The Future of Bone Regeneration.
SEM osteoblasts, magnification 400X
Mesentech developed a novel that can deliver medicines selectively to the bone. Our first drug candidate, C3, reverses bone loss.
Mesentech's bone anabolic drug conjugates will be incrementally developed as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. A topical formulation is being developed as a bone graft material to speed osseointegration in orthopedic and oral-maxillofacial indications while avoiding the cost and morbidity associated with harvesting self-donor material for autografts.
Executive Team
Robert Young
Founder & President
• 30+ years leading discovery at Merck resulting in $80B+ in revenue from development of Singulair®. Vioxx®, Arcoxia®, Previcox®, Tredaptive® and odanacatib • Recipient of Heros of Chemistry award and the Order of Canada award • Two time recipient of Prix Galien (UK and Canada)
Jon Polak
CEO
• Head of Business Development at Novateur Ventures • Founder and former CEO of Datapoint Diagnostics • Co-founder of C7bio • Deep international experience in clinical development, financing, regulatory strategy, pharmaceutical partnerships, recruiting angel investors, asset sale and patenting • Speaks 5 languages having lived and worked in China, Israel, Brazil, US & Canada.
Michael Underhill
Co-founder & Chief Science Officer
• Leading foundational research on mechanisms underlying bone formation • Co-founder of Corigen and Nexigen • Professor of Microbiology & Immunology at UBC
Peter Savas
Executive Chairman
• Serial CEO with 8 positive exists for shareholders • Current CEO of Likeminds • Formerly CEO of Alseres Pharma • Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® trans-dermal patch marketed worldwide to treat Parkinson’s disease • Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials • leadership positions with Bristol Meyers, Waters, Millipore, Genex and Zymark.
Learn more about our
If you are interested in partnering, we’d love to hear from you
774-234-8018
2222 Health Sciences Mall
Vancouver, British Columbia V6T1Z3
Canada
774-234-8018
2222 Health Sciences Mall
Vancouver, British Columbia V6T1Z3
Canada
